Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

DFP-10917

DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride

DRUG

Cytarabine

cytosine arabinoside (ara-C)

DRUG

Azacitidine

Azacitidine

DRUG

Decitabine

Decitabine

DRUG

Mitoxantrone

Mitoxantrone

DRUG

Etoposide

Etoposide

DRUG

Fludarabine

Fludarabine

DRUG

Idarubicin

Idarubicin

DRUG

Venetoclax

Venetoclax

DRUG

Cladribine

Cladribine

Trial Locations (39)

10595

RECRUITING

New York Medical College, Valhalla

22903

RECRUITING

University of Virginia Health System, Charlottesville

27103

RECRUITING

Novant Health Cancer Institute - Forsyth (Hematology), Winston-Salem

27157

RECRUITING

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

27834

RECRUITING

East Carolina University, Greenville

28204

RECRUITING

Novant Health Cancer Institute - Elizabeth (Hematology), Charlotte

28501

RECRUITING

Vidant Oncology, Kinston

29605

RECRUITING

Prisma Health Cancer Institute, Greenville

30912

RECRUITING

Georgia Cancer Center at Augusta University, Augusta

32207

RECRUITING

Baptist MD Anderson, Jacksonville

32209

RECRUITING

UF-Health Jacksonville, Jacksonville

32608

RECRUITING

UF-Health Cancer Center Gainesville, Gainesville

32804

RECRUITING

AdventHealth Medical Group Blood and Marrow Transplant at Orlando, Orlando

35294

RECRUITING

O'Neal Comprehensive Cancer Center, Birmingham

39216

RECRUITING

The University of Mississippi Medical Center, Jackson

40241

SUSPENDED

Norton Cancer Institute, Louisville

40536

RECRUITING

University of KY- Markey Cancer Center, Lexington

44106

RECRUITING

Seidman Cancer Center, University Hospitals, Cleveland Medical Center, Cleveland

44718

RECRUITING

Gabrail Cancer Center, Canton

45267

RECRUITING

University of Cincinnati Cancer Center, Cincinnati

46237

RECRUITING

Franciscan Health Indianapolis, Indianapolis

48202

RECRUITING

Henry Ford Cancer Institute, Detroit

57105

RECRUITING

Avera Medical Group, Sioux Falls

60153

RECRUITING

Loyola University Medical Center, Hines

60612

RECRUITING

Rush University, Chicago

62526

RECRUITING

Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur

66205

RECRUITING

The University of Kansas Cancer Center, Westwood

70118

RECRUITING

Tulane University, New Orleans

70121

ACTIVE_NOT_RECRUITING

Ochsner Benson Cancer Center, Jefferson

75390

RECRUITING

UT Southwestern, Dallas

77030

RECRUITING

Baylor College of Medicine, Houston

RECRUITING

MD Anderson Cancer Center, Houston

85234

RECRUITING

Banner MD Anderson, Gilbert

85258

RECRUITING

HonorHealth (VGPCC Cancer Transplant Institute), Scottsdale

90095

RECRUITING

UCLA, Los Angeles

92697

RECRUITING

University of California, Irvine

99218

RECRUITING

Multicare Institute for Research and Innovation, Spokane

85724-5024

RECRUITING

The University of Arizona Cancer Center, Tucson

05401

RECRUITING

University of Vermont Medical Center, Burlington

Sponsors
All Listed Sponsors
lead

Delta-Fly Pharma, Inc.

INDUSTRY

NCT03926624 - Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | Biotech Hunter | Biotech Hunter